ConforMIS Inc. (NASDAQ:CFMS) CEO Philipp Lang sold 53,860 shares of the stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $10.19, for a total transaction of $548,833.40. Following the transaction, the chief executive officer now owns 483,378 shares of the company’s stock, valued at approximately $4,925,621.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Philipp Lang also recently made the following trade(s):
- On Tuesday, October 4th, Philipp Lang sold 400 shares of ConforMIS stock. The stock was sold at an average price of $10.00, for a total transaction of $4,000.00.
- On Monday, October 3rd, Philipp Lang sold 10,410 shares of ConforMIS stock. The stock was sold at an average price of $10.03, for a total transaction of $104,412.30.
ConforMIS Inc. (NASDAQ:CFMS) opened at 10.12 on Thursday. ConforMIS Inc. has a 1-year low of $4.80 and a 1-year high of $23.62. The stock’s market cap is $426.33 million. The company has a 50-day moving average of $8.80 and a 200 day moving average of $8.80.
ConforMIS (NASDAQ:CFMS) last released its earnings results on Monday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.01. ConforMIS had a negative net margin of 84.33% and a negative return on equity of 45.30%. The business earned $19.30 million during the quarter, compared to analyst estimates of $18.02 million. During the same quarter in the prior year, the firm earned ($2.51) earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Analysts predict that ConforMIS Inc. will post ($1.40) EPS for the current year.
Several large investors have recently added to or reduced their stakes in CFMS. Raymond James & Associates acquired a new stake in ConforMIS during the second quarter worth about $113,000. Oak Ridge Investments LLC acquired a new stake in ConforMIS during the second quarter worth about $127,000. American International Group Inc. raised its stake in ConforMIS by 242.6% in the second quarter. American International Group Inc. now owns 20,584 shares of the company’s stock worth $144,000 after buying an additional 14,575 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in ConforMIS during the second quarter worth about $147,000. Finally, Nationwide Fund Advisors raised its stake in ConforMIS by 276.7% in the second quarter. Nationwide Fund Advisors now owns 22,932 shares of the company’s stock worth $161,000 after buying an additional 16,845 shares during the last quarter. 41.13% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently issued reports on the stock. B. Riley assumed coverage on shares of ConforMIS in a report on Wednesday, September 21st. They issued a “buy” rating and a $13.00 target price for the company. SunTrust Banks Inc. assumed coverage on shares of ConforMIS in a report on Monday, September 19th. They issued a “buy” rating and a $14.00 target price for the company. JPMorgan Chase & Co. lowered their target price on shares of ConforMIS from $11.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, August 9th. Oppenheimer Holdings Inc. raised their target price on shares of ConforMIS from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, August 9th. Finally, Zacks Investment Research upgraded shares of ConforMIS from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. ConforMIS presently has a consensus rating of “Buy” and a consensus price target of $14.86.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.
Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.